Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
This study compares two different schedules of a chemotherapy drug called cisplatin combined with radiation therapy for head and neck cancer. Doctors want to see if giving a lower dose of chemotherapy weekly is easier for patients to tolerate while still working just as well as the standard higher dose given every three weeks.
Adults with advanced squamous cell cancer of the head, neck, or throat who meet specific tissue test requirements, such as a positive p16 protein marker, may be able to join. You cannot participate if your cancer has spread to distant parts of the body or if you have previously received cisplatin or overlapping radiation therapy.
Participants will receive radiation therapy alongside either weekly or once-every-three-weeks doses of cisplatin chemotherapy. Throughout the study, you will undergo imaging scans like CT, MRI, or PET scans and complete surveys about your well-being and health.
This study has multiple locations across the United States, including sites in Alabama and Arkansas. Please note that this study is currently suspended, meaning new participants are not being enrolled at this moment.
- 1Compares weekly versus every-three-weeks cisplatin chemotherapy combined with radiation.
- 2Aims to find out if the weekly schedule is better tolerated without losing effectiveness.
- 3Currently suspended for new participant enrollment across its locations.
Related video
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.